Aptevo Therapeutics Inc. (APVO) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001671584 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | — | $-6.4M | $-5.31 | Filing |
| Mar 31, 2026 | May 13, 2026 | — | $-6.7M | $-6.41 | Filing |
| Dec 31, 2025 | Mar 26, 2026 | — | $-5.8M | $1648.06 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | — | $-7.5M | $-2.23 | Filing |
| Jun 30, 2025 | Aug 11, 2025 | — | $-6.2M | $-151.29 | Filing |
| Mar 31, 2025 | Apr 28, 2025 | — | $-6.4M | $-1581.81 | Filing |
| Dec 31, 2024 | Feb 14, 2025 | — | $-6.3M | $-29497.20 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | — | $-5.1M | $-357.86 | Filing |
What would Aptevo Therapeutics Inc. have to report for its valuation to change?
At $1.62, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -84.7% a year, to $0.14. On that path the next quarter needs diluted EPS near $-0.34, against $-2.23 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -84.7% | -84.7% |
| EPS needed in final year | $0.14 | $0.14 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. APVO goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.